Counterpoint Mutual Funds LLC Acquires Shares of 2,071 IQVIA Holdings Inc. $IQV

Key Points

• Counterpoint Mutual Funds LLC acquired 2,071 shares of IQVIA Holdings Inc., valued at approximately $326,000, during the second quarter.
• IQVIA reported strong earnings of $2.81 per share for the latest quarter, exceeding analysts' expectations, with revenue up 5.3% year-over-year.
• The stock has received multiple positive ratings from analysts, with a consensus "Moderate Buy" rating and a target price of $229.64.

Counterpoint Mutual Funds LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,071 shares of the medical research company's stock, valued at approximately $326,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. American National Bank & Trust purchased a new position in shares of IQVIA in the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA in the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $181.25 on Thursday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $238.56. The stock has a market cap of $30.81 billion, a PE ratio of 26.23, a P/E/G ratio of 2.05 and a beta of 1.32. The firm has a 50-day simple moving average of $186.37 and a two-hundred day simple moving average of $167.39. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the business earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group raised their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Jefferies Financial Group upgraded shares of IQVIA from a "hold" rating to a "buy" rating and raised their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, Evercore ISI raised their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Eighteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.